Cassava Sciences: Phase 3 Alzheimer’s Drug Fail The Final Nail In The Coffin

Summary:

• Cassava Sciences’ Alzheimer’s drug simufilam failed to meet primary, secondary, and exploratory endpoints in its Phase 3 ReThink-ALZ study, leading to the discontinuation of further trials.
• SAVA stock plummeted from $26.5 to $4 per share following the negative study results, casting doubt on the company’s future prospects.
• Cassava’s remaining $149m cash and lack of ongoing R&D expenses may lead to delisting or a reverse merger with another biotech firm.
• The failure of simufilam underscores the challenges in developing effective Alzheimer’s treatments, with Cassava likely exiting the AD drug development space.

Cassava Sciences Investment Overview

I covered Cassava Sciences’ (NASDAQ:SAVA) Q3 earnings earlier this month – a low-key affair from which most of the key figures behind the company’s extraordinary rise, fall, rise, and fall again story were absent, including even the current Chief Medical

Analyst’s Disclosure: I/we have a beneficial long position in the shares of SAVA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.